Get the Stockscreener App
26.45
0.64%
-0.17
After Hours:
26.91
0.46
+1.74%
Xoma Royalty Corp stock is traded at $26.45, with a volume of 732.65K.
It is down -0.64% in the last 24 hours and down -11.57% over the past month.
XOMA Royalty Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceuticals or biotechnology companies. XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes. Geographically, the company operates in Switzerland, United States, Asia Pacific, Europe and Others.
See More
Previous Close:
$26.62
Open:
$26.36
24h Volume:
732.65K
Relative Volume:
5.75
Market Cap:
$327.53M
Revenue:
$9.71M
Net Income/Loss:
$-29.96M
P/E Ratio:
-7.6006
EPS:
-3.48
Net Cash Flow:
$-14.79M
1W Performance:
+1.03%
1M Performance:
-11.57%
6M Performance:
-1.89%
1Y Performance:
+0.69%
1-Day Range:
$25.55
$26.92
1-Week Range:
$25.30
$28.61
52-Week Range:
$18.35
$39.92
Xoma Royalty Corp Stock (XOMA) Company Profile
Name
Xoma Royalty Corp
Sector
Industry
Phone
510-204-7239
Address
2200 POWELL STREET, EMERYVILLE, CA
Compare XOMA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
XOMA
Xoma Royalty Corp
|
26.45 | 329.64M | 9.71M | -29.96M | -14.79M | -3.48 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.38 | 113.87B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.54 | 80.22B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
406.40 | 52.56B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
803.74 | 49.31B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.07 | 37.37B | 447.02M | -1.18B | -906.14M | -6.1812 |
Xoma Royalty Corp Stock (XOMA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-17-25 | Initiated | The Benchmark Company | Buy |
| Apr-29-24 | Initiated | Leerink Partners | Outperform |
| Sep-07-21 | Downgrade | Wedbush | Outperform → Neutral |
| Jun-29-21 | Initiated | Aegis Capital | Buy |
| Jan-19-21 | Reiterated | H.C. Wainwright | Buy |
| Jan-18-18 | Reiterated | H.C. Wainwright | Buy |
| Oct-17-17 | Resumed | H.C. Wainwright | Buy |
| Sep-05-17 | Upgrade | Wedbush | Neutral → Outperform |
| Jun-12-17 | Initiated | H.C. Wainwright | Buy |
| Nov-14-16 | Downgrade | Wedbush | Outperform → Neutral |
| Mar-11-16 | Reiterated | Wedbush | Outperform |
| Jul-23-15 | Downgrade | Jefferies | Buy → Hold |
| Jul-22-15 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Jul-22-15 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Oct-10-14 | Resumed | ROTH Capital | Buy |
| Apr-29-14 | Upgrade | MLV & Co | Hold → Buy |
| Mar-11-14 | Downgrade | MLV & Co | Buy → Hold |
| Mar-05-14 | Reiterated | Ladenburg Thalmann | Buy |
| Oct-31-13 | Reiterated | MLV & Co | Buy |
| May-09-13 | Reiterated | Ladenburg Thalmann | Buy |
| May-14-12 | Initiated | Cowen & Co | Outperform |
| Mar-31-11 | Reiterated | MLV Capital | Buy |
| Mar-23-11 | Reiterated | RBC Capital Mkts | Outperform |
| Jan-06-11 | Reiterated | Ladenburg Thalmann | Buy |
| Jan-04-11 | Reiterated | Wedbush | Outperform |
View All
Xoma Royalty Corp Stock (XOMA) Latest News
Will XOMA Royalty Corporation (X0M1) stock profit from fiscal stimulus2026 world cup usa national team quarterfinals top scorers counter attacking tactical prediction breakdown - Улправда
Takeda, XOMA ink new royalty agreement; amend existing deal - MSN
Xoma royalty corp sees sale of $16.98 million in stock by investors - MSN
Antibody Development Company Cleared to Pursue Royalties for Tremfya, Judge Rules - Law.com
Can XOMA Royalty Corporation stock double in next 5 yearsTechnical Analysis Insights & Free Trend Following Techniques - bollywoodhelpline.com
Leerink Partners reiterates Outperform rating on XOMA stock at $45 target - Investing.com India
XOMA and Takeda execute royalty sharing transaction - The Pharma Letter
Takeda regains majority of mezagitamab royalty interest from XOMA - Investing.com
XOMA Royalty: Entitled to Payments Associated - 富途牛牛
Drug royalties reshuffled as XOMA trades part of one for nine experimental drugs - Stock Titan
XOMA Royalty Corporation (NASDAQ:XOMA) Short Interest Up 31.7% in December - MarketBeat
XOMA Royalty (XOMAO) Stock Analysis Report | Financials & Insights - Benzinga
XOMA Royalty Declares Quarterly Preferred Stock Dividends - Sahm
XOMA Royalty Corporation Announces Cash Dividends for Preferred Stockholders - Quiver Quantitative
Institutional Owners May Consider Drastic Measures as XOMA Royalty Corporation's (NASDAQ:XOMA) Recent US$57m Drop Adds to Long-term Losses - 富途牛牛
XOMA Royalty (NASDAQ:XOMA) shareholders have earned a 13% CAGR over the last three years - Yahoo Finance
Turnstone Biologics To Merge With Biotech Royalty Aggregator XOMA, But Retail Sentiment Slumps - MSN
Weekly Buzz: CYTK Scores First FDA Approval, INSM Ends Rhinosinusitis Study, XOMA Acquires GBIO - RTTNews
Can XOMA Royalty Corporation stock deliver strong Q4 earningsRate Hike & Smart Investment Allocation Insights - Улправда
Generation Bio is latest Mass. biotech to be acquired by Xoma - The Business Journals
Jefferies downgrades Generation Bio stock to Hold as XOMA acquisition announced - Investing.com
‘Zombie’ biotech buyer Xoma to acquire Generation Bio - Yahoo Finance
XOMA Royalty Corporation to Acquire Generation Bio Co. in Cash Transaction with Milestone and Royalty Opportunities - Quiver Quantitative
XOMA Royalty Enters into Agreement to Acquire Generation Bio - GlobeNewswire
Investors Don't See Light At End Of XOMA Royalty Corporation's (NASDAQ:XOMA) Tunnel - simplywall.st
FY2025 EPS Estimates for XOMA Royalty Reduced by Analyst - MarketBeat
BVF Inc. IL Has $65.28 Million Stock Position in XOMA Royalty Corporation $XOMA - MarketBeat
XOMA stock maintains Buy rating at Benchmark despite partner’s trial setback - Investing.com
Xoma announces closing of transactions to acquire Lava Therapeutics - MSN
XOMA: HC Wainwright Maintains Buy Rating, Lowers Price Target to $97 | XOMA Stock News - GuruFocus
Leerink Partners lowers XOMA stock price target on RZ358 trial failure By Investing.com - Investing.com South Africa
HC Wainwright & Co. Maintains XOMA Royalty (XOMA) Buy Recommendation - Nasdaq
Why two Bay Area companies' stocks tumbled on a drug's clinical failure - The Business Journals
Leerink Partners lowers XOMA stock price target on RZ358 trial failure - Investing.com Canada
XOMA stock price target lowered to $97 by H.C. Wainwright - Investing.com Australia
XOMA: Leerink Partners Lowers Price Target, Reiterates Outperfor - GuruFocus
Why Is XOMA Royalty Stock Sinking Thursday?Rezolute (NASDAQ:RZLT), XOMA Royalty (NASDAQ:XOMA) - Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga
LUCID CAPITAL MARKETS Initiates Coverage of XOMA Royalty (XOMA) with Buy Recommendation - Nasdaq
Lucid Capital Markets initiates coverage on XOMA stock with Buy rating - Investing.com Canada
XOMA Royalty (XOMA): New Buy Rating Initiated by Lucid Capital M - GuruFocus
XOMA Royalty Corp CEO Owen Hughes Acquires 100,000 Depositary Shares - TradingView — Track All Markets
Mural Oncology Announces Sanction of the Scheme by the High Court - 富途牛牛
XOMA (NASDAQ:XOMAO) Trading 0.8% Higher – Time to Buy? - Defense World
XOMA Royalty completes acquisition of Mural Oncology for $2.035 per share - Investing.com Nigeria
XOMA Royalty completes acquisition of Mural Oncology By Investing.com - Investing.com Nigeria
Xoma announces closing of transaction to acquire Mural Oncology - TipRanks
Mural Oncology Announces Effectiveness of Scheme of Arrangement and Completion of Acquisition - Research Tree
Xoma Royalty announces closing of transaction to acquire Mural Oncology plc - marketscreener.com
Xoma Royalty Corp Stock (XOMA) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.52%
0.07%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):